117 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
37
Identification of High-Potency Human TLR8 and Dual TLR7/TLR8 Agonists in Pyrimidine-2,4-diamines.
University of Minnesota
14
Incorporation of Phosphonate into Benzonaphthyridine Toll-like Receptor 7 Agonists for Adsorption to Aluminum Hydroxide.
Genomics Institute of Novartis Research Foundation
6
Structural requirements for TLR7-selective signaling by 9-(4-piperidinylalkyl)-8-oxoadenine derivatives.
Glaxosmithkline
22
Dihydropyrrolo[2,3-d]pyrimidines: Selective Toll-Like Receptor 9 Antagonists from Scaffold Morphing Efforts.
Sumitomo Dainippon Pharma
20
Synthesis and evaluation of 8-oxoadenine derivatives as potent Toll-like receptor 7 agonists with high water solubility.
Dainippon Sumitomo Pharma
6
Discovery of Imidazoquinolines with Toll-Like Receptor 7/8 Independent Cytokine Induction.
TBA
16
Toll-like receptor (TLR)-7 and -8 modulatory activities of dimeric imidazoquinolines.
University of Kansas
21
Preliminary evaluation of a 3H imidazoquinoline library as dual TLR7/TLR8 antagonists.
University of Kansas
3
Toward self-adjuvanting subunit vaccines: model peptide and protein antigens incorporating covalently bound toll-like receptor-7 agonistic imidazoquinolines.
University of Kansas
20
Design and optimisation of orally active TLR7 agonists for the treatment of hepatitis C virus infection.
Pfizer
7
Syntheses of fluorescent imidazoquinoline conjugates as probes of Toll-like receptor 7.
University of Kansas
18
Structure-activity relationships in human toll-like receptor 7-active imidazoquinoline analogues.
University of Kansas
16
Synthesis and biological evaluation of 8-oxoadenine derivatives as toll-like receptor 7 agonists introducing the antedrug concept.
Dainippon Sumitomo Pharma
2
Regioisomerism-dependent TLR7 agonism and antagonism in an imidazoquinoline.
University of Kansas
17
Discovery of Novel Isoxazole-Based Small-Molecule Toll-Like Receptor 8 Antagonists.
University of Bonn
24
Structure-Based Design of Novel TLR7/8 Agonist Payloads Enabling an Immunomodulatory Conjugate Approach.
Bristol Myers Squibb
6
Novel Imidazo[4,5-c]pyridine Compounds as TLR7 Agonists for Treating Cancer.
Smith Gambrell & Russell LLP
9
Modulation of the Adjuvant Potential of Imidazoquinoline-Based TLR7/8 Agonists via Alum Adsorption.
Panjab University
1
Antibody-drug conjugates for targeted cancer therapy: Recent advances in potential payloads.
Shaoxing University
1
Exploration of 1-(indolin-1-yl)-2-(thiazol-2-yl)ethan-1-one derivatives as novel anti-HBV agent with potential TLR7-agonistic effect.
Xuzhou Medical University
23
Heterocyclic-Modified Imidazoquinoline Derivatives: Selective TLR7 Agonist Regulates Tumor Microenvironment against Melanoma.
Southern Medical University
21
Design, Synthesis, and Biological Evaluation of New 2,6,7-Substituted Purine Derivatives as Toll-like Receptor 7 Agonists for Intranasal Vaccine Adjuvants.
Gwangju Institute of Science and Technology
17
Structure-Activity Relationships toward the Identification of a High-Potency Selective Human Toll-like Receptor-7 Agonist.
Panjab University
27
Synthesis and Optimization of 1-Substituted Imidazo[4,5-
Binghamton University School of Pharmacy and Pharmaceutical Sciences
27
Discovery of the TLR7/8 Antagonist MHV370 for Treatment of Systemic Autoimmune Diseases.
Novartis Institutes for Biomedical Research
27
Identification and Optimization of Small Molecule Pyrazolopyrimidine TLR7 Agonists for Applications in Immuno-oncology.
Bristol Myers Squibb
33
Discovery of Novel TLR7 Agonists as Systemic Agent for Combination With aPD1 for Use in Immuno-oncology.
Bristol Myers Squibb
43
Small-Molecule Modulators Targeting Toll-like Receptors for Potential Anticancer Therapeutics.
West China Hospital
34
Generation and structure-activity relationships of novel imidazo-thienopyridine based TLR7 agonists: application as payloads for immunostimulatory antibody drug-conjugates.
Zymeworks
6
Novel Thienopyrrole Compounds for Treating Autoimmune Diseases and Inflammatory Conditions.
Smith, Gambrell & Russell
195
Structural evolution of toll-like receptor 7/8 agonists from imidazoquinolines to imidazoles.
Panjab University
50
If small molecules immunotherapy comes, can the prime be far behind?
Zhejiang University
10
Agonist and antagonist ligands of toll-like receptors 7 and 8: Ingenious tools for therapeutic purposes.
University of Montpellier
15
Structural Evolution and Translational Potential for Agonists and Antagonists of Endosomal Toll-like Receptors.
Csir-Indian Institute of Chemical Biology
9
Toll-like receptor 7 and 8 imidazoquinoline-based agonist/antagonist pairs.
University of Minnesota
34
Identification of 2-Pyridinylindole-Based Dual Antagonists of Toll-like Receptors 7 and 8 (TLR7/8).
Biocon Bristol Myers Squibb Research Center (Bbrc)
41
Development, Optimization, and In Vivo Validation of New Imidazopyridine Chemotypes as Dual TLR7/TLR9 Antagonists through Activity-Directed Sequential Incorporation of Relevant Structural Subunits.
Csir-Indian Institute of Chemical Biology
4
Covalently Conjugated NOD2/TLR7 Agonists Are Potent and Versatile Immune Potentiators.
University of Ljubljana
25
Small molecule approaches to treat autoimmune and inflammatory diseases (Part II): Nucleic acid sensing antagonists and inhibitors.
Roche Innovation Center Shanghai
14
Structure-Based Optimization of a Fragment-like TLR8 Binding Screening Hit to an
Novartis Institutes For Biomedical Research
30
Systematic Optimization of Potent and Orally Bioavailable Purine Scaffold as a Dual Inhibitor of Toll-Like Receptors 7 and 9.
Csir-Indian Institute of Chemical Biology
66
Structure-Based Design of Highly Potent Toll-like Receptor 7/8 Dual Agonists for Cancer Immunotherapy.
Beijing Advanced Innovation Center For Human Brain Protection
6
Novel Triazatricycle Compounds for Treating Autoimmune Diseases.
Smith, Gambrell & Russell
6
Novel Carbazoles for Treating Inflammatory and Autoimmune Diseases.
Smith, Gambrell & Russell
61
Synthesis and characterization of new potent TLR7 antagonists based on analysis of the binding mode using biomolecular simulations.
Csir-Indian Institute of Chemical Biology
40
Identification of a Human Toll-Like Receptor (TLR) 8-Specific Agonist and a Functional Pan-TLR Inhibitor in 2-Aminoimidazoles.
University of Kansas
15
Discovery of potent, orally bioavailable in vivo efficacious antagonists of the TLR7/8 pathway.
Genomics Institute of The Novartis Research Foundation
32
Discovery of GS-9688 (Selgantolimod) as a Potent and Selective Oral Toll-Like Receptor 8 Agonist for the Treatment of Chronic Hepatitis B.
Gilead Sciences
26
Potent and Selective Inhibitors of MTH1 Probe Its Role in Cancer Cell Survival.
AstraZeneca
14
Optimization of 8-oxoadenines with toll-like-receptor 7 and 8 activity.
University of Montana
35
Discovery of Potent and Orally Bioavailable Small Molecule Antagonists of Toll-like Receptors 7/8/9 (TLR7/8/9).
Princ
28
Target-Based Identification and Optimization of 5-Indazol-5-yl Pyridones as Toll-like Receptor 7 and 8 Antagonists Using a Biochemical TLR8 Antagonist Competition Assay.
Genomics Institute of The Novartis Research Foundation
14
Synthesis and immunostimulatory activity of sugar-conjugated TLR7 ligands.
Kagoshima University
13
Further exploration of the structure-activity relationship of imidazoquinolines; identification of potent C7-substituted imidazoquinolines.
University of Kansas
12
A Chemical Switch for Transforming a Purine Agonist for Toll-like Receptor 7 to a Clinically Relevant Antagonist.
Csir-Indian Institute of Chemical Biology
3
Discovery of a First-in-Class Receptor Interacting Protein 2 (RIP2) Kinase Specific Clinical Candidate, 2-((4-(Benzo[
Glaxosmithkline
20
Novel and Selective TLR7 Antagonists among the Imidazo[1,2-
University of Montpellier
32
Discovery of Novel Small Molecule Dual Inhibitors Targeting Toll-Like Receptors
University of Colorado Boulder
18
Selective Toll-like receptor 7 agonists with novel chromeno[3,4-d]imidazol-4(1H)-one and 2-(trifluoromethyl)quinoline/ quinazoline-4-amine scaffolds.
University of Ljubljana
14
Structure-activity relationship analysis of imidazoquinolines with Toll-like receptors 7 and 8 selectivity and enhanced cytokine induction.
University of Minnesota
34
Activity-guided development of potent and selective toll-like receptor 9 antagonists.
Csir-Indian Institute of Chemical Biology
12
Toll-like Receptors for the Treatment of Autoimmune, Inflammation, and Infectious Diseases.
Usona Institute
35
Discovery of Novel Small-Molecule Inhibitors of NF-κB Signaling with Antiinflammatory and Anticancer Properties.
University of Colorado
22
Design and Synthesis of N1-Modified Imidazoquinoline Agonists for Selective Activation of Toll-like Receptors 7 and 8.
University of Minnesota
17
Design and development of benzoxazole derivatives with toll-like receptor 9 antagonism.
Csir-Indian Institute of Chemical Biology
47
Identification and Optimization of Pyrrolo[3,2-d]pyrimidine Toll-like Receptor 7 (TLR7) Selective Agonists for the Treatment of Hepatitis B.
Janssen Pharmaceutica
3
Discovery of Small Molecules as Multi-Toll-like Receptor Agonists with Proinflammatory and Anticancer Activities.
University of Colorado Boulder
1
Crystalline form of capsid protein assembly inhibitor containing N hetero five-membered ring, and application thereof
Chia Tai Tianqing Pharmaceutical Group
69
HETEROCYCLIC G-PROTEIN-COUPLED RECEPTOR 52 (GPR52) AGONISTS
University Of Texas
381
3-(1H-IMIDAZOL-2-YL)-2,3,8,8A-TETRAHYDROINDOLIZIN-5(1H)-ONE DERIVATIVES USEFUL AS FACTOR XIA INHIBITORS
Janssen Pharmaceutica
7
NOVEL TRICYCLIC AROMATIC HETEROCYCLIC COMPOUND AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF
Shanghai Longwood Biopharmaceuticals
78
Compounds for the treatment of BRAF-associated diseases and disorders
Array Biopharma
97
Formulations of Tie-2 activators and methods of use thereof
Eyepoint Pharmaceuticals
16
JAK kinase inhibitor compounds for treatment of respiratory disease
Theravance Biopharma R&D Ip
17
Compounds as neuronal histamine receptor-3 antagonists and uses thereof
Xw Laboratories
47
Substituted pyrazolo/imidazolo bicyclic compounds as PDE2 inhibitors
Merck Sharp & Dohme
14
Chemokine CXCR1 and CXCR2 receptor antagonist compounds, and use thereof in the treatment of chemokine-mediated pathologies
Galderma Research & Development
514
6-hydroxy-5-(phenyl/heteroarylsulfonyl)pyrimidin-4(1H)-one as APJ agonists
Bristol Myers Squibb
234
Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
Enanta Pharmaceuticals
96
Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer
Loxo Oncology
17
Synthesis and biological evaluation of novel series of aminopyrimidine derivatives as urease inhibitors and antimicrobial agents.
Solapur University
19
Substituted pyrrolidines as factor xia inhibitors for the treatment thromboembolic diseases
Ono Pharmaceutical
11
Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives
Reviva Pharmaceuticals
31
Use of 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors
Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F.
8
Tricyclic heterocycles useful as dipeptidyl peptidase-IV inhibitors
Merck Sharp & Dohme
67
Nitrogen-containing spirocyclic compounds and pharmaceutical uses thereof
Japan Tobacco